<DOC>
	<DOCNO>NCT00290615</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , cetuximab bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab bevacizumab may also stop growth tumor cell block blood flow tumor . Giving capecitabine together cetuximab , oxaliplatin , bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine together cetuximab , oxaliplatin , bevacizumab work treat patient metastatic recurrent colorectal cancer remove surgery .</brief_summary>
	<brief_title>Capecitabine , Cetuximab , Oxaliplatin , Bevacizumab Treating Patients With Metastatic Recurrent Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient unresectable metastatic recurrent colorectal adenocarcinoma treat capecitabine , cetuximab , oxaliplatin , bevacizumab . Secondary - Determine safety tolerability regimen patient . - Determine progression-free overall survival patient treat regimen . Exploratory - Determine effect regimen angiogenesis biomarkers patient . - Determine effect regimen wound angiogenesis patient . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 . Patients also receive cetuximab IV 1-2 hour , oxaliplatin IV 2 hour , bevacizumab IV 30-90 minute day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month . PROJECTED ACCRUAL : Approximately 45 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Unresectable disease Metastatic recurrent disease Not amenable potentially curative treatment No untreated leptomeningeal brain metastasis PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 No known uncontrolled coagulopathy Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Bilirubin &lt; 2.0 time ULN Renal Creatinine clearance &gt; 40 mL/min Urine protein negative Urine protein : creatinine ratio &gt; 1 Cardiovascular No unstable uncontrolled hypertension ( i.e. , blood pressure [ BP ] &gt; 150/100 mm Hg despite antihypertensive therapy ) Patients recently start adjust antihypertensive medication eligible provide BP &lt; 140/90 mm Hg ≥ 3 different measurement 14 day No arterial thromboembolic event within past 6 month , include follow : Transient ischemic attack Cerebrovascular accident Unstable angina Myocardial infarction Clinically significant peripheral vascular disease No New York Heart Association class IIIIV congestive heart failure No uncontrolled symptomatic coronary artery disease cardiac arrhythmia No significant uncontrolled cardiac disease Gastrointestinal No lack physical integrity upper gastrointestinal tract No malabsorption syndrome No inability tolerate oral medication Immunologic No prior severe infusion reaction monoclonal antibody No history allergic reaction attribute compound similar chemical biologic composition oxaliplatin , cetuximab , capecitabine , bevacizumab No prior unanticipated , severe reaction fluoropyrimidine therapy know hypersensitivity fluoroucacil Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 34 month completion study treatment No peripheral neuropathy ≥ grade 2 No malignancy within past 5 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix No known dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY : Biologic therapy No prior adjuvant bevacizumab cetuximab No concurrent anticancer immunotherapy biologic therapy Chemotherapy At least 6 month since prior adjuvant fluorouracil , leucovorin calcium , capecitabinebased regimen At least 12 month since prior adjuvant oxaliplatin No prior chemotherapy metastatic recurrent disease Endocrine therapy No concurrent hormonal therapy Radiotherapy No concurrent radiotherapy Surgery More 4 week since prior major surgery recover More 6 month since vascular surgery , stenting , angioplasty Other At least 4 week since prior concurrent sorivudine brivudine More 4 week since prior participation investigational drug study No prior therapy affect target epidermal growth factor pathway No concurrent cimetidine Concurrent ranitidine , famotidine , protonpump inhibitor allow Concurrent anticoagulation therapy fulldose anticoagulant allow provide dose stable least 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>